title: Treatment of experimental renal osteodystrophy with pamidronate.
abstract: We evaluated the effects of the bisphosphonate pamidronate on bone histomorphometry, structure and strength in male rats with uninephrectomy or with chronic renal disease induced by 5/6 nephrectomy. In rats with chronic renal disease the plasma urea, phosphate and parathyroid hormone levels were significantly increased compared to rats with a uninephroctomy and none of these parameters was affected by pamidronate treatment. In the femoral midshaft, chronic renal disease reduced cortical bone mineral density and content. No difference was observed in the breaking load of the femoral midshaft. In the distal femur, a high-turnover renal osteodystrophy was found but pamidronate suppressed this bone turnover and increased bone mineral content. Treatment had no effect on chronic disease-induced augmentation of osteoid volume or fibroblast surface. These studies show that in this model of stage 3 renal disease, pamidronate increased mineral content in the femoral midshaft and distal metaphysis primarily by adding bone to endocortical and trabecular surfaces but did not reduce osteitis fibrosa.
authors.affiliation: Department of Orthopaedics, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Jarkko
authors.initials: J
authors.lastname: Jokihaara
authors.forename: Ilkka H
authors.initials: IH
authors.lastname: Pörsti
authors.forename: Peeter
authors.initials: P
authors.lastname: Kööbi
authors.forename: Pasi M
authors.initials: PM
authors.lastname: Jolma
authors.forename: Jukka T
authors.initials: JT
authors.lastname: Mustonen
authors.forename: Heikki H T
authors.initials: HH
authors.lastname: Saha
authors.forename: Harri
authors.initials: H
authors.lastname: Sievänen
authors.forename: Pekka
authors.initials: P
authors.lastname: Kannus
authors.forename: Urszula T
authors.initials: UT
authors.lastname: Iwaniec
authors.forename: Russell T
authors.initials: RT
authors.lastname: Turner
authors.forename: Teppo L N
authors.initials: TL
authors.lastname: Järvinen
mesh_terms: D000818:Animals; D018488:Bone Demineralization, Pathologic / Q000188:drug therapy / Q000209:etiology; D015519:Bone Density / Q000187:drug effects; D016723:Bone Remodeling / Q000187:drug effects; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000188:drug therapy* / Q000209:etiology; D004164:Diphosphonates / Q000494:pharmacology* / Q000627:therapeutic use; D005269:Femur / Q000473:pathology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy; D008297:Male; D009392:Nephrectomy; D000077268:Pamidronate; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D004164:Diphosphonates; D000077268:Pamidronate